Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 13/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24589131 | 0.87 | AHR (0.66) | AHRSMN1; SMN2TTRKDM4EMEN1 | |
| SCHEMBL24296146 | 0.82 | AHR (0.70) | AHRSMN1; SMN2TTRKDM4EMEN1 | |
| SCHEMBL23690166 | 0.81 | AHR (0.58) | AHRSMN1; SMN2TTRESR2KDM4E | |
| SCHEMBL2286537 | 0.81 | AHR (1.00) | AHRSMN1; SMN2TTR | |
| SCHEMBL26347545 | 0.79 | AHR (0.47) | AHRSMN1; SMN2ESR2KDM4EMEN1 | |
| SCHEMBL22172059 | 0.79 | AHR (0.47) | AHRSMN1; SMN2ESR2KDM4EMEN1 | |
| SCHEMBL24296577 | 0.79 | AHR (0.51) | AHRSMN1; SMN2TTRKDM4EMEN1 | |
| SCHEMBL24074104 | 0.78 | AHR (0.50) | AHRSMN1; SMN2TTRESR2KDM4E | |
| SCHEMBL24589016 | 0.78 | AHR (0.64) | AHRSMN1; SMN2ESR2KDM4EMEN1 | |
| SCHEMBL23690158 | 0.78 | AHR (0.50) | AHRSMN1; SMN2TTRESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220209139-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | LG DISPLAY CO., LTD (KR) | 2022-06-30 | — | — | US | disclosed |
| US-20210234104-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND AMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220209139-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | OCIAD1, OCIAD2, OLA1 | AHR 2196/4885SMN1; SMN2 639/4885TTR 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.